ISSN: 1300 - 6525 E-ISSN: 2149 - 0880
kulak burun boğaz
ve baş boyun cerrahisi dergisi
http://dergi.kbb-bbc.org.tr
Kayıtlı İndeksler
ORIGINAL RESEARCH
Is Modified Systemic Inflammation Score a Predictor of Malignancy in Indeterminate Thyroid Nodules?
Modifiye Sistemik İnflamasyon Skoru, İndetermine Tiroid Nodüllerinde Malignitenin Bir Göstergesi midir?
Received Date : 03 Jan 2023
Accepted Date : 20 Feb 2023
Available Online : 23 Feb 2023
Özet PDF Benzer Makaleler
Yaşar Kemal DUYMAZa, Ahmet Mahmut TEKİNb, Serap ÖNDERc, Şamil ŞAHİNd, Burak ERKMENe, Fatih SAVRANf, Cumhur Selçuk TOPALg
aDepartment of Otolaryngology, Ümraniye Training and Research Hospital University of Health Sciences, İstanbul, Türkiye bDepartment of Otolaryngology, Vrije Universiteit, Brussel, Belgium cClinic of Otorhinolaryngology, Acıbadem Ataşehir Hospital, İstanbul, Türkiye dPrivate Physician, İstanbul, Türkiye eDepartment of Otolaryngology, University of Health Sciences Sancaktepe Martyr Prof Dr İlhan Varank Training and Research Hospital, İstanbul, Türkiye fClinic of Otorhinolaryngology, Private Sancaktepe Bölge Hospital, İstanbul, Türkiye gDepartment of Pathology, University of Health Sciences Ümraniye Training and Research Hospital, İstanbul, Türkiye
Doi: 10.24179/kbbbbc.2023-95264 - Makale Dili: EN
KBB ve BBC Dergisi. 2023;31(2):109-14
Copyright © 2020 by Turkey Association of Society of Ear Nose Throat and Head Neck Surgery. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ABSTRACT
Objective: The aim of this study is to evaluate the preoperative diagnostic value of modified systemic inflammation score (mSIS) in predicting the presence of malignancy in patients with indeterminate thyroid nodules. Matherials and Methods: It is a retrospective study. 368 patients who underwent thyroid lobectomy were screened. Patients were divided into 3 groups according to modified SIS; mSIS 0 for those were Albumin (Alb) ≥ 4.0 gr/dL and Lymphocyte Monocyte Ratio (LMR) ≥ 3.4 , mSIS 1 for those were Alb<4.0 gr/dL or LMR<3.4, mSIS 2 for those were Alb<4.0 gr/dL and LMR<3.4. According to the results of the postoperative pathology, the patients were divided into two groups as benign and malignant. Results: The malignancy was found in 24 patients in histopathological examination. 10 (41.7%) of these were micropapillary, 8 (33.3%) were papillary and 6 (25%) were follicular carcinomas. There was no difference between the malignant and benign groups in terms of LMR and Albumin values. mSIS 0 had a 65% malignancy rate, mSIS 1 69.2%, and mSIS 2 66.6%. There was no statistically significant difference between the groups. Conclusion: MSIS may not be a predictor of malignancy in indeterminate thyroid nodules. Further studies are needed to understand this issue.
Keywords: Modified systemic inflammation score; thyroid lobectomy; indeterminate thyroid nodule; Bethesda classification
ÖZET
Amaç: Bu çalışmanın amacı belirsiz tiroid nodülü olan hastalarda malignite varlığını öngörmede modifiye sistemik inflamasyon skorunun (mSIS) preoperatif tanısal değerini araştırmaktır. Gereç-Yöntem: Retrospektif bir çalışmadır. Tiroid lobektomi yapılan 368 hasta tarandı. Modifiye SIS'e göre hastalar 3 gruba ayrıldı; Albümin (Alb) ≥ 4,0 gr/dL ve Lenfosit Monosit Oranı (LMR) ≥ 3,4 olanlar mSIS 0, Alb <4,0 gr/dL veya LMR <3,4 olanlar mSIS 1, Alb <4,0 gr/dL ve LMR<3.4 olanlar mSIS 2. Postoperatif patoloji sonuçlarına göre hastalar benign ve malign olarak iki gruba ayrıldı. Bulgular: Histopatolojik incelemede 24 hastada malignite saptandı. Bunların 10'u (%41,7) mikropapiller, 8'i (%33,3) papiller ve 6'sı (%25) foliküler karsinomdu. Malign ve benign gruplar arasında LMR ve Albümin değerleri açısından fark yoktu. mSIS 0'da malignite oranı %65, mSIS 1'de %69,2 ve mSIS 2'de %66,6 idi. Gruplar arasında istatistiksel olarak anlamlı fark yoktu. Sonuç: MSIS, indetermine tiroid nodüllerinde malignitenin bir göstergesi olmayabilir. Bu konuyu anlamak için daha ileri çalışmalara ihtiyaç vardır.
Anahtar Kelimeler: Modifiye sistemik inflamasyon skoru; tiroid lobektomi; indetermine tiroid nodülü; Bethesda sınıflandırması
KAYNAKLAR
  1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. [Crossref]  [PubMed]  [PMC] 
  2. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341-6. [Crossref]  [PubMed] 
  3. Bongiovanni M, Bellevicine C, Troncone G, Sykiotis GP. Approach to cytological indeterminate thyroid nodules. Gland Surg. 2019;8(Suppl 2):S98-S104. [Crossref]  [PubMed]  [PMC] 
  4. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33 Suppl 1:S79-84. [Crossref]  [PubMed] 
  5. Jackson D, Handelsman RS, Farrá JC, Lew JI. Increased incidental thyroid cancer in patients with subclinical chronic lymphocytic thyroiditis. J Surg Res. 2020;245:115-8. [Crossref]  [PubMed] 
  6. Paparodis RD, Karvounis E, Bantouna D, Chourpiliadis C, Chourpiliadi H, Livadas S, et al. Incidentally discovered papillary thyroid microcarcinomas are more frequently found in patients with chronic lymphocytic thyroiditis than with multinodular goiter or graves' disease. Thyroid. 2020;30(4):531-5. [Crossref]  [PubMed] 
  7. Chen YK, Lin CL, Cheng FT, Sung FC, Kao CH. Cancer risk in patients with Hashimoto's thyroiditis: a nationwide cohort study. Br J Cancer. 2013;109(9):2496-501. [Crossref]  [PubMed]  [PMC] 
  8. Ghoshal A, Garmo H, Arthur R, Carroll P, Holmberg L, Hammar N, et al. Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum. Oncotarget. 2017;9(1):774-82. [Crossref]  [PubMed]  [PMC] 
  9. Yokota M, Katoh H, Nishimiya H, Kikuchi M, Kosaka Y, Sengoku N, et al. Lymphocyte-monocyte ratio significantly predicts recurrence in papillary thyroid cancer. J Surg Res. 2020;246:535-43. [Crossref]  [PubMed] 
  10. Shrihari TG. Inflammation-related cancer or cancer-related inflammation. Eur Res J. 2017;3:1-5. [Crossref] 
  11. Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):971-8. [Crossref]  [PubMed] 
  12. Khandia R, Munjal A. Interplay between inflammation and cancer. Adv Protein Chem Struct Biol. 2020;119:199-245. [Crossref]  [PubMed] 
  13. Xiong J, Kang W, Ma F, Liu H, Ma S, Li Y, et al. Modified systemic inflammation score is an independent predictor of long-term outcome in patients undergoing surgery for adenocarcinoma of the esophagogastric junction. Front Surg. 2021;8:622821. [Crossref]  [PubMed]  [PMC] 
  14. Del Rio P, Pisani P, Montana Montana C, Cataldo S, Marina M, Ceresini G. The surgical approach to nodule Thyr 3-4 after the 2.2014 NCCN and 2015 ATA guidelines. Int J Surg. 2017;41 Suppl 1:S21-5. [Crossref]  [PubMed] 
  15. Kanda M, Koike M, Tanaka C, Kobayashi D, Hattori N, Hayashi M, et al. Modified systemic inflammation score is useful for risk stratification after radical resection of squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2019;26(13):4773-81. [Crossref]  [PubMed] 
  16. Huang H, Chen LM, Fang XJ, Guo CC, Lin XP, Hong HM, et al. Prognostic value of the modified systemic inflammation score in patients with extranodal natural killer/T-cell lymphoma. Front Pharmacol. 2020;11:593392. [Crossref]  [PubMed]  [PMC] 
  17. Jiang C, Xiu Y, Yu X, Qiao K, Zhang S, Huang Y. Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy. BMC Cancer. 2022;22(1):1249. [Crossref]  [PubMed]  [PMC] 
  18. Wang F, Chen L, Wang Z, Xu Q, Huang H, Wang H, et al. Prognostic value of the modified systemic inflammation score in non-small-cell lung cancer with brain metastasis. Cancer Cell Int. 2022;22(1):320. [Crossref]  [PubMed]  [PMC] 
  19. Morkavuk ŞB, Çulcu S, Esen E, Ünal AE. The diagnostic value of modified systemic ınflammation score in predicting post-operative outcomes of cutaneous melanoma patients who underwent ısolated limb perfusion. World J Surg Oncol. 2021;19(1):327. [Crossref]  [PubMed]  [PMC] 
  20. Xu M, Wu Q, Cai L, Sun X, Xie X, Sun P. Systemic inflammatory score predicts overall survival in patients with cervical cancer. J Cancer. 2021;12(12):3671-7. [Crossref]  [PubMed]  [PMC] 
  21. Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kimura K, et al. The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer. Oncol Lett. 2018;16(1):666-72. [Crossref]  [PubMed]  [PMC] 
  22. Nomoto D, Baba Y, Akiyamam T, Okadome K, Iwatsuki M, Iwagami S, et al. Adapted systemic inflammation score as a novel prognostic marker for esophageal squamous cell carcinoma patients. Ann Gastroenterol Surg. 2021;5(5):669-76. [Crossref]  [PubMed]  [PMC] 
  23. Ataş H, Korukluoğlu B, Çomçali B, Yakşi N, Saylam B, Tez M. Can preoperative modified systemic inflammation score (mSIS) be used to predict malignancy in persistent nondiagnostic thyroid nodules? Turk J Med Sci. 2021;51(2):700-5. [Crossref]  [PubMed]  [PMC] 
  24. Ataş H, Korukluoğlu B, Özdemir BA, Yakşi N, Saylam B, Tez M. Diagnostic value of modified systemic inflammation score for prediction of malignancy in patients with indeterminate thyroid nodules. Am J Surg. 2021;221(1):117-21. [Crossref]  [PubMed] 
  25. Li N, Fu S, Cui MM, Niu Y, Li B, Liu ZP, et al. Platelet distribution width and serum albumin levels for discrimination of thyroid cancer from benign thyroid nodules. Asian Pac J Cancer Prev. 2017;18(7):1773-7. [PubMed]  [PMC] 
  26. Kocer D, Karakukcu C, Karaman H, Gokay F, Bayram F. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders? Asian Pac J Cancer Prev. 2015;16(9):3875-9. [Crossref]  [PubMed] 
Copyright © 2024
Yasal uyarı: Bu sitede yayınlanan resim, yazı ve diğer uygulamaların her hakkı Kulak Burun Boğaz Baş ve Boyun Cerrahisi Derneği'ne aittir. Kaynak gösterilmeden kullanılamaz. Bu site hekimleri sağlık alanında bilgilendirmeye yönelik hazırlanmıştır. Sitede yer alan bilgiler tanı ve tedavi amaçlı kullanıldığında sorumluluk tamamen kullanıcıya aittir. Siteye girmekle bu şartları okumuş, anlamış ve kabul etmiş sayılırsınız.
Site Tasarım ve Yönetim: Türkiye Klinikleri